Castle BiosciencesCSTL
CSTL
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
272% more call options, than puts
Call options by funds: $3.7M | Put options by funds: $996K
44% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 27
5% more funds holding
Funds holding: 184 [Q3] → 194 (+10) [Q4]
1.23% more ownership
Funds ownership: 93.08% [Q3] → 94.31% (+1.23%) [Q4]
3% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 64
4% less capital invested
Capital invested by funds: $737M [Q3] → $704M (-$32.8M) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 2 (-2) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$37
84%
upside
Avg. target
$39
94%
upside
High target
$41
104%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Baird Catherine Ramsey 50% 1-year accuracy 8 / 16 met price target | 84%upside $37 | Outperform Maintained | 28 Feb 2025 |
Stephens & Co. Mason Carrico 32% 1-year accuracy 9 / 28 met price target | 104%upside $41 | Overweight Reiterated | 2 Jan 2025 |
Financial journalist opinion
Based on 5 articles about CSTL published over the past 30 days
Neutral
Business Wire
2 weeks ago
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests for patients with skin cancers at the 2025 AAD Annual Meeting.

Neutral
Seeking Alpha
3 weeks ago
Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Subbu Nambi - Guggenheim Sung Ji Nam - Scotiabank Thomas Flaten - Lake Street Paul Knight - KeyBanc Mason Carrico - Stephens Tom Peterson - Baird Vidyun Bais - BTIG Kyle Mikson - Canaccord Operator Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2024 Conference Call. As a reminder, today's call is being recorded.

Positive
Zacks Investment Research
3 weeks ago
Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.10 per share a year ago.

Neutral
Business Wire
4 weeks ago
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #diagnostics--Castle Biosciences, Inc. (Nasdaq: CSTL), today announced its financial results for the fourth quarter and year ended December 31, 2024.

Neutral
Business Wire
4 weeks ago
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management is scheduled to present a company overview at two investor conferences next month.

Positive
Zacks Investment Research
1 month ago
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
Castle Biosciences' fourth-quarter 2024 earnings are likely to have gained from higher test volume growth of its dermatologic and non-dermatologic tests.

Positive
Zacks Investment Research
1 month ago
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 50.8% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Neutral
Business Wire
1 month ago
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will share data supporting its dermatologic portfolio of GEP tests at the 2025 Winter Clinical Dermatology Conference - Hawaii, Feb. 14-19.

Positive
Zacks Investment Research
1 month ago
Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock
Castle Biosciences (CSTL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Charts implemented using Lightweight Charts™